Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pulmonary fibrosis: patterns and perpetrators.

Noble PW, Barkauskas CE, Jiang D.

J Clin Invest. 2012 Aug;122(8):2756-62. doi: 10.1172/JCI60323. Epub 2012 Aug 1. Review.

2.

Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis.

Barkauskas CE, Noble PW.

Am J Physiol Cell Physiol. 2014 Jun 1;306(11):C987-96. doi: 10.1152/ajpcell.00321.2013. Epub 2014 Apr 16. Review.

3.

New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis.

Ding Q, Luckhardt T, Hecker L, Zhou Y, Liu G, Antony VB, deAndrade J, Thannickal VJ.

Drugs. 2011 May 28;71(8):981-1001. doi: 10.2165/11591490-000000000-00000. Review.

4.
5.

Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment.

Liu M, Ren D, Wu D, Zheng J, Tu W.

Curr Stem Cell Res Ther. 2015;10(6):466-76. Review.

PMID:
25986617
6.

Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally.

Smith ML.

Arch Pathol Lab Med. 2016 Mar;140(3):221-9. doi: 10.5858/arpa.2015-0288-SA. Review.

PMID:
26927716
7.

[The mechanism of lung tissue remodeling in the progression of idiopathic pulmonary fibrosis].

Kogan EA, Tyong FV, Demura SA.

Arkh Patol. 2010 Jul-Aug;72(4):30-6. Russian.

PMID:
21086635
8.

[Idiopathic pulmonary fibrosis].

Doubková M, Skhicková J.

Vnitr Lek. 2005 Dec;51(12):1375-84. Review. Czech.

PMID:
16430105
9.

Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis.

du Bois RM, Wells AU.

Eur Respir J Suppl. 2001 Sep;32:43s-55s. Review.

10.

Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.

Fellrath JM, du Bois RM.

Clin Exp Med. 2003 Sep;3(2):65-83. Review.

PMID:
14598183
11.
12.

New tale for an old fox in IPF?

Mercer PF, Chambers RC.

Am J Physiol Lung Cell Mol Physiol. 2013 Apr 1;304(7):L466-8. doi: 10.1152/ajplung.00286.2012. Epub 2013 Jan 11. No abstract available.

13.

Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach?

Mahendran S, Sethi T.

QJM. 2012 Oct;105(10):929-34. Epub 2012 May 29. Review.

PMID:
22647761
14.

Signaling pathways in the epithelial origins of pulmonary fibrosis.

Hardie WD, Hagood JS, Dave V, Perl AK, Whitsett JA, Korfhagen TR, Glasser S.

Cell Cycle. 2010 Jul 15;9(14):2769-76. Epub 2010 Jul 3. Review.

15.

Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis.

Kliment CR, Englert JM, Gochuico BR, Yu G, Kaminski N, Rosas I, Oury TD.

J Biol Chem. 2009 Feb 6;284(6):3537-45. doi: 10.1074/jbc.M807001200. Epub 2008 Dec 9.

16.

Linking progression of fibrotic lung remodeling and ultrastructural alterations of alveolar epithelial type II cells in the amiodarone mouse model.

Birkelbach B, Lutz D, Ruppert C, Henneke I, Lopez-Rodriguez E, Günther A, Ochs M, Mahavadi P, Knudsen L.

Am J Physiol Lung Cell Mol Physiol. 2015 Jul 1;309(1):L63-75. doi: 10.1152/ajplung.00279.2014. Epub 2015 May 8.

17.

Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications.

Spagnolo P, Rossi G, Cavazza A.

Expert Rev Clin Immunol. 2014 Aug;10(8):1005-17. doi: 10.1586/1744666X.2014.917050. Epub 2014 Jun 23. Review.

PMID:
24953006
18.

[Innovative therapeutics for idiopathic pulmonary fibrosis].

Uzunhan Y, Nunes H, Gille T, Bron C, Planès C, Valeyre D.

Presse Med. 2011 Dec;40(12 Pt 1):1100-12. doi: 10.1016/j.lpm.2011.07.009. Epub 2011 Sep 3. Review. French.

PMID:
21890312
19.

[Idiopathic pulmonary fibrosis: from biopathology to treatment].

Wallaert B, Lamblin C.

Rev Prat. 2000 Nov 1;50(17):1906-10. French.

PMID:
11151332
20.

Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?

Huie TJ, Brown KK.

Respir Investig. 2015 May;53(3):88-92. doi: 10.1016/j.resinv.2014.12.005. Epub 2015 Mar 4. Review.

PMID:
25951093

Supplemental Content

Support Center